FDA: Page


  • Some payments exempt from Sunshine Act pharma database reporting

    The Obama admin has decided that in certain cases, companies don't have to report payments to physicians who participate in CME events, especially if they're funded by non-commercial sources.

    By • Nov. 5, 2014
  • India-based Wockhardt's profits plummet as it faces continued FDA export ban

    Indian exports have dropped by 90% compared with 2012 since last year's export ban, which probably won't be lifted until at least next year. But Wockhardt's stock is up 70% this year on buy-out rumors.

    By • Nov. 4, 2014
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Will Boehringer win an asthma indication for Spiriva Respimat?

    If approved, Spiriva Respimat Inhalation Spray will provide asthma patients with another treatment option—and be the first new approved inhaled therapy for asthma patients in over a decade.

    By • Nov. 4, 2014
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Feds probe whether US officials engaged in insider trading over Dendreon drug

    The SEC is aggressively investigating insider trading allegations that date back to 2010 and center on a review of Dendreon's prostate cancer drug, Provenge. 

    By • Nov. 3, 2014
  • Uh-oh: 2/3 of UK docs defying new statin guidelines

    The controversial and aggressive new statin guidelines continue to expose rifts within the medical community.

    By • Nov. 3, 2014
  • Express Scripts gearing up to snub Gilead in favor of AbbVie hep C drug

    Express Scripts' medical chief made it clear last week that the company's looking for an HCV treatment that is as effective as Gilead's Sovaldi (sofosbuvir)—but cheaper.

    By • Nov. 3, 2014
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    FDA panel endorses approval of Daaichi's blood clot, stroke drug

    If approved, edoxaban, a once-daily factor Xa inhibitor, will become the third FXa inhibitor available in the U.S.—and it may become the biggest seller in its class, according to experts.

    By • Nov. 3, 2014
  • Pfizer's meningitis drug becomes first FDA-approved breakthrough therapy

    Trumenba, Pfizer's meningococcal group B vaccine, was approved by the FDA's Center for Biologics Evaluation and Research (CBER) after an expedited four-month review.

    By • Oct. 31, 2014
  • AZ scores FDA approval of once-daily diabetes fixed-dose combo pill

    Xigduo XR is the first once-daily fixed-dose combination of an SGLT2​ inhibitor (Farxiga/dapagliflozin) and metformin to win FDA approval.

    By • Oct. 30, 2014
  • US senators propose FDA vouchers to expedite Ebola drug development

    Lawmakers have proposed a voucher system that would give drug developers an expedited review in order to encourage the creation of as many Ebola treatments as possible.

    By • Oct. 30, 2014
  • Deep Dive

    Diving into the future of fixed-dose combos

    From respiratory disease to HIV therapeutics, fixed-dose combinations are an important part of drug development. The regulatory hurdles are high—but so are the rewards.

    By • Oct. 30, 2014
  • India to ban use of plastic bottles for liquid drugs

    Drug manufacturers aren't pleased with the decision.

    By • Oct. 30, 2014
  • Feds announce new Ebola guidelines

    The new guidelines establish four tiers of risk.

    By Katie Bo Williams • Oct. 29, 2014
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    UPDATED: Judge slashes Actos class action award from $9 billion to $36.8 million

    Lilly and Takeda breathe a sigh of relief. 

    By • Oct. 29, 2014
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Sarepta's mega-orphan Duchenne's drug faces more roadblocks

    The FDA's demand for yet more data means eteplirsen approval is not likely before 2016. Sarepta's stock was down 35% on the news.

    By • Oct. 28, 2014
  • EU panel recommends approval of Clinuvel's sunburn-prevention drug

    Scenesse (afamelanotide) was developed by Australia-based Clinuvel for prevention of severe sunburn in patients with a rare genetic disease that renders them intolerant to light.

    By • Oct. 27, 2014
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    FDA approves Baxter's hemophilia orphan drug

    Obizur (antihemophilic factor, porcine sequence) is the breakthrough FDA-approved treatment for acquired hemophilia A—an extremely rare disease. 

    By • Oct. 27, 2014
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    EMA recommends approval of AZ's ovarian cancer drug

    Lynparza (olararib) is a first-in-class treatment for ovarian cancer that is being widely hailed as a breakthrough. 

    By • Oct. 27, 2014
  • EU reverses course, won't cede drug-related decisions to pharma

    President-elect Jean-Claude Juncker's plan to shift the EMA from the Directorate General (DG) for Health and Consumers to DG Enterprise and Industry has been scrapped after considerable backlash.

    By • Oct. 24, 2014
  • EMA establishes expedited review framework for Ebola vaccines

    The European Medicines Agency (EMA) has established an elite group of infectious disease specialists to help rapidly review Ebola vaccine submissions.

    By • Oct. 24, 2014
  • Deep Dive

    Best of BD: Biosimilars in China: The coming revolution

    Despite a less rigorous approach to approving biosimilars, China has several approved follow-on biologics—and a growing number of biotechs want to develop biosimilars that meet global standards.

    By • Oct. 22, 2014
  • Lilly, Boehringer fixed-dose diabetes combo could win FDA blessing soon

    The FDA has agreed to review the empagliflozin/metformin fixed-dose combo from Eli Lilly and Boehringer Ingelheim.

    By • Oct. 22, 2014
  • Study: Parkinson's disease drugs make some patients want to party

    The dopamine agonists used to treat Parkinson's patients can sometimes lead to an obsession with gambling and pornography, research finds.

    By • Oct. 22, 2014
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    How the FDA plans to stop facilities from undermining inspections

    New FDA guidance regarding conduct during facility inspections outlines expectations for manufacturers—and for the FDA.

    By • Oct. 22, 2014
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    PhRMA fights back, blames insurance companies for drug access woes

    AccessBetterCoverage.org is choc-full of insurance facts. But its real message is that health insurers, and not pharma, are guilty of shifting drug costs onto consumers.

    By • Oct. 21, 2014